文献速递妇科

复发性卵巢癌合并不可手术恶性肠梗阻患者管理策略的成本效益分析

Cost-effectiveness of management strategies for patients with recurrent ovarian cancer and inoperable malignant bowel obstruction.
PubMed 文献 · Gynecol Oncol · 2022-11-04

本研究从社会视角采用蒙特卡洛模拟比较四种管理策略(临终关怀、全肠外营养、化疗、全肠外营养+化疗)用于铂耐药复发性卵巢癌合并不可手术恶性肠梗阻患者。结果显示全肠外营养+化疗成本最高且获得最高质量调整生命年,但与临终关怀相比的增量成本效益比为918,538美元/质量调整生命年。在150,000美元/质量调整生命年的社会支付意愿阈值下,临终关怀在71.6%的案例中为优选策略。结论认为全肠外营养联合或不联合化疗在此情境下不具有成本效益。

要点

  • 全肠外营养+化疗策略成本最高(49,741美元)且质量调整生命年最高(0.089)。
  • 与临终关怀相比,全肠外营养+化疗的增量成本效益比为918,538美元/质量调整生命年。
  • 在150,000美元/质量调整生命年阈值下,临终关怀在71.6%的案例中为优选策略。

核心结论

  • 全肠外营养联合或不联合化疗在不可手术恶性肠梗阻和铂耐药卵巢癌的管理中不具有成本效益。

研究设计与样本

  • 从社会视角采用蒙特卡洛模拟比较四种管理策略:临终关怀、全肠外营养、化疗、全肠外营养+化疗。
  • 生存、住院率、临终地点和恶性肠梗阻相关效用值来自文献综述:临终关怀(生存38天,住院率6%)、化疗(42天,29%)、全肠外营养(55天,25%)、全肠外营养+化疗(74天,47%)。
  • 结局指标为各策略的平均成本和每获得一个质量调整生命年的增量成本效益比(美元/质量调整生命年)。

主要发现

  • 基础案例分析中,全肠外营养+化疗为成本最高的策略(均值;95%CI)(49,741美元;49,329-50,162美元),并提供最高的质量调整生命年(0.089;0.089-0.090)。
  • 成本最低的策略为临终关怀(14,591美元;14,527-14,654美元)。
  • 全肠外营养单独和化疗单独策略被临终关怀与全肠外营养+化疗的组合策略所支配。
  • 全肠外营养+化疗与临终关怀相比的增量成本效益比为918,538美元/质量调整生命年。
  • 在社会支付意愿阈值为150,000美元/质量调整生命年时,临终关怀在71.6%的案例中为优选策略,化疗单独在28.4%的案例中为优选策略,含全肠外营养的策略在0%的案例中为优选策略。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Patients with recurrent platinum-resistant ovarian cancer often present with inoperable malignant bowel obstruction (MBO) from a large burden of abdominal disease. Interventions such as total parenteral nutrition (TPN) and chemotherapy may be used in this setting. We aim to describe the relative cost-effectiveness of these interventions to inform clinical decision making. METHODS: Four strategies for management of platinum-resistant recurrent ovarian cancer with inoperable MBO were compared from a societal perspective using a Monte Carlo simulation: (1) hospice, (2) TPN, (3) chemotherapy, and (4) TPN + chemotherapy. Survival, hospitalization rates, end-of-life (EOL) setting, and MBO-related utilities were obtained from literature review: hospice (survival 38 days, 6% hospitalization), chemotherapy (42 days, 29%), TPN (55 days, 25%), TPN + chemotherapy (74 days, 47%). Outcomes were the average cost per strategy and incremental cost-effectiveness ratios (ICERs) in US dollars per quality-adjusted life year (QALY) gained. RESULTS: In the base case scenario, TPN + chemotherapy was the most costly strategy (mean; 95% CI) ($49,741; $49,329-$50,162) and provided the highest QALYs (0.089; 0.089-0.090). The lowest cost strategy was hospice ($14,591; $14,527-$14,654). The TPN alone and chemotherapy alone strategies were dominated by a combination of hospice and TPN + chemotherapy. The ICER of TPN + chemotherapy was $918,538/QALY compared to hospice. With a societal willingness to pay threshold of $150,000/QALY, hospice was the strategy of choice in 71.6% of cases, chemotherapy alone in 28.4%, and TPN-containing strategies in 0%. CONCLUSIONS: TPN with or without chemotherapy is not cost-effective in management of inoperable malignant bowel obstruction and platinum-resistant ovarian cancer.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Peters PN, Moyett JM, Davidson BA, et al. Cost-effectiveness of management strategies for patients with recurrent ovarian cancer and inoperable malignant bowel obstruction. Gynecol Oncol. 2022. PMID: 36344293. doi:10.1016/j.ygyno.2022.10.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。